Posted by Michael Wonder on 27 Feb 2026
Dupixent (dupilumab) recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatment
27 February 2026 - Regeneron Pharmaceuticals and Sanofi today announced that the EMA’s CHMP adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for the treatment of chronic spontaneous urticaria.
This recommendation covers children aged 2 to 11 years with moderate to severe chronic spontaneous urticaria, an inadequate response to histamine 1 anti-histamines and who are naïve to anti-immunoglobulin E therapy for chronic spontaneous urticaria.
